Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines adherence and medicines optimisation inseparable, RPS tells NICE

By News team

Medicines adherence and medicines optimisation are inseparable, argues the Royal Pharmaceutical Society in response to a National Institute for Health and Care Excellence scoping exercise. NICE excludes the concept of medicines adherence from its draft scope on medicines optimisation.

“We strongly believe that it is not possible to separate medicines optimisation and medicines adherence. The ultimate goal of medicines optimisation is to ensure better adherence to medicines with the aim of getting the best outcomes for patients from their medicines. Medicines optimisation without medicines adherence is pointless,” the RPS says. It adds: “The two are inseparable, in our opinion as even if you prescribe the right medicines for the right patient at the right time, if the patient is not supported to take that medicine through a shared decision-making process then they are unlikely to achieve the best outcomes possible.”

The RPS also points out that medicines adherence, and therefore, medicines optimisation, could result in patients choosing not to take a particular medicine as part of an informed, shared decision-making process.

It notes that NICE’s earlier adherence advice will be signposted as an additional resource in the medicines optimisation guidance, but argues that medicines adherence should be integral to the medicines optimisation recommendations.

The RPS also criticises the definition of medicines optimisation in NICE’s scope, adding that it should be more “positive, and action and patient focused”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11128499

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Clinical Pharmaceutics (An)

    Introduction to Clinical Pharmaceutics (An)

    This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.

    £27.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.